Advances in the Early Diagnosis and Management of Renal Diseases

Dear Colleagues,

The last decade has seen a number of advances in the diagnostics and management of glomerulopathies, interstitial and hypertensive nephropathy, kidney stone disease, vasculitis, and diabetic kidney disease.

Since the progressive loss of functioning renal tissue may result from a number of different disturbances (congenital hypoplasia or obstructive uropathy with or without associated infections, other anomalies, polycystic kidneys, chronic pyelonephritis, glomerulonephritis, etc.), an exact diagnosis is essential to establish the appropriate therapy.

With a few exceptions, invasive diagnostics—namely, a kidney biopsy—are currently required for the precise diagnosis of many chronic kidney diseases. In order to effectively develop personalized medicine for renal diseases, we urgently need to develop highly accurate biomarkers for use in the clinic since the current biomarkers of kidney damage (creatinine and/or urine albumin excretion) apply to later stages of the disease. A promising, non-invasive approach is urinary proteome analysis, which has the potential to identify various types of renal disease. Renal failure, a consequence of renal disease progression, is among the most deadly and economically costly diseases faced by patients and modern society. Despite this, there are relatively few new therapies in development for the treatment of renal disease. Multiple factors have contributed to the diminishing interest in pharmaceutical investment in the field of renal disease. Many costly phase 3 trials have failed to provide improved renal outcomes, and the awareness of renal diseases remains poor among patients, physicians, and payers. Nevertheless, several therapeutics remain in development for the treatment of CKD, including mineralocorticoid receptor antagonists, sodium/glucose cotransporter 2 inhibitors, anti-inflammatory drugs, and drugs that mitigate oxidative injury.

The success of the future management of renal disease will depend not only on an improved understanding of disease pathogenesis but also on increasing awareness of this disease among the public and the greater medical community, as well as quick diagnostics and appropriate treatment.

Prof. Dr. Mariusz A. Kusztal
Prof. Dr. Kinga Musiał
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• chronic kidney disease
• glomerulonephritis
• biomarkers
• kidney biopsy
• treatment